<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011542</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-10-1-0593</org_study_id>
    <nct_id>NCT02011542</nct_id>
  </id_info>
  <brief_title>Probiotic (VSL #3) for Gulf War Illness</brief_title>
  <official_title>Probiotics (VSL #3) for Gulf War Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to determine whether VSL #3 will improve 1) intestinal symptoms of
      Irritable Bowel Syndrome (IBS) and 2) non-intestinal symptoms (fatigue, joint pain, insomnia,
      general stiffness and headache) associated with IBS. All of these symptoms are part of the
      Gulf War (GW) illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      Aim # 1: Determine the efficacy of VSL #3 on IBS symptoms in GW veterans.

      Hypothesis: Treatment with VSL #3 compared to placebo will improve global and individual
      symptoms of IBS

      Aim #2 Determine the efficacy VSL #3 in reducing non-intestinal symptoms of IBS (fatigue,
      joint pain, insomnia, general stiffness and headache).

      Hypothesis: Treatment with VSL #3 compared to placebo will improve non-intestinal symptoms of
      IBS in GW veterans.

      Aim #3 Determine whether changes in gut flora and plasma cytokines correlate with treatment
      response in GW veterans.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Original study product (VSL #3) became unavailable; change in study Collaborator and product
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in the Bowel Symptom Scale (BSS) From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Efficacy of VSL #3 in Irritable Bowel Syndrome (IBS) related symptoms in Gulf War illness is measured using BSS at 2, 4, 6, 8 wks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Chronic Fatigue (1-5 Scale) From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Efficacy of VSL #3 in reducing non-intestinal symptoms of IBS is measured using chronic fatigue scale at 2,4,6,8, weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Gulf War Illness</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (not an active drug/ Inactive component) is given to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSL #3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VSL #3 (probiotic mixture) is given to this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>This is a probiotic mixture</description>
    <arm_group_label>VSL #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a pill with inactive ingredients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo/ Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First GW veterans, Men and women age 35-75 years,

          2. Rome III criteria for IBS and two or more of the non-intestinal symptoms (chronic-once
             a week or more often-fatigue, joint pains, insomnia, general stiffness, and headache)

          3. Symptoms of &gt; 6 months duration,

          4. No significant findings on physical examination, Complete Blood Count (CBC) and
             clinical chemistry panel.

          5. Normal gross appearance of the colonic mucosa other than erythema and polyps

          6. Negative Tissue transglutaminase (TTG) for celiac disease,

          7. Normal thyroid function.

          8. Veterans with psychological disorders will not be excluded but will be identified for
             sub-group analysis.

          9. Stable medication regimen for more than a month

        Exclusion Criteria:

          1. Current evidence of any lower gastrointestinal disorder such as celiac disease or
             inflammatory bowel disease

          2. History of/or presence of systemic malignancy (patients with skin and other cancers in
             remission for more than 5 years are allowed in the study

          3. Clinically significant chronic disease: HIV, cardiac, pulmonary, hepatic or renal
             dysfunction.

          4. Presence of Giardia antigen, and Clostridium difficile toxin in stool,

          5. Abnormal blood test for thyroid stimulating hormone, tissue transglutaminase antibody

          6. Current effects of drug or alcohol abuse

          7. Investigator perception of patient's inability to comply with study protocol

          8. Recent change in gastrointestinal medications

          9. Use of any antibiotic in the last 1 months

         10. Positive pregnancy test

         11. Subject is currently participating in another research protocol that could interfere
             or influence the outcome measures of the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>George E Wahlen VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <results_first_submitted>December 12, 2017</results_first_submitted>
  <results_first_submitted_qc>December 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 16, 2018</results_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Office of Research and Development</investigator_affiliation>
    <investigator_full_name>Ashok K. Tuteja</investigator_full_name>
    <investigator_title>Professor Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Gulf War Illness</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study is ongoing; information on enrolled participant arm assignment is blinded, therefore these arms/groups are combined</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VSL #3 or Placebo</title>
          <description>Study participants enrolled into the VSL #3 arm or the Placebo arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</population>
      <group_list>
        <group group_id="B1">
          <title>VSL #3 or Placebo</title>
          <description>Study participants enrolled into the VSL #3 arm or the Placebo arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in the Bowel Symptom Scale (BSS) From Baseline</title>
        <description>Efficacy of VSL #3 in Irritable Bowel Syndrome (IBS) related symptoms in Gulf War illness is measured using BSS at 2, 4, 6, 8 wks</description>
        <time_frame>8 weeks</time_frame>
        <population>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</population>
        <group_list>
          <group group_id="O1">
            <title>VSL #3 or Placebo</title>
            <description>Study participants enrolled into the VSL #3 arm or the Placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in the Bowel Symptom Scale (BSS) From Baseline</title>
          <description>Efficacy of VSL #3 in Irritable Bowel Syndrome (IBS) related symptoms in Gulf War illness is measured using BSS at 2, 4, 6, 8 wks</description>
          <population>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Chronic Fatigue (1-5 Scale) From Baseline</title>
        <description>Efficacy of VSL #3 in reducing non-intestinal symptoms of IBS is measured using chronic fatigue scale at 2,4,6,8, weeks</description>
        <time_frame>8 weeks</time_frame>
        <population>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</population>
        <group_list>
          <group group_id="O1">
            <title>VSL #3 or Placebo</title>
            <description>Study participants enrolled into the VSL #3 arm or the Placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Chronic Fatigue (1-5 Scale) From Baseline</title>
          <description>Efficacy of VSL #3 in reducing non-intestinal symptoms of IBS is measured using chronic fatigue scale at 2,4,6,8, weeks</description>
          <population>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</desc>
      <group_list>
        <group group_id="E1">
          <title>VSL #3 or Placebo</title>
          <description>Study participants enrolled into the VSL #3 arm or the Placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ashok Tuteja</name_or_title>
      <organization>University of Utah, Dept. of Gastroenterology</organization>
      <phone>801-581-5679</phone>
      <email>ashok.tuteja@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

